I gave an opinion based on what has happened so far. The only significant news was lympro commercialization and so far we have only one deal that doesn't call for any near term revenue. Amarantus has yet to give any details what so ever about Lympro and revenue. Why do you think that is? If something bigger is brewing, then great. But could it also be that Lympro was let out of the barn prematurely? Look, I get it that you and others are so emotionally in love with this stock that you can't be objective but we will just have to agree to disagree. If I am proven to be wrong, then great because I actually want to make money on this investment. The science is great but unfortunately management hasn't yet been able to capitalize on anything. Fair enough?